Stifel Nicolaus Weisel and Canaccord Genuity Inc. are acting as joint book-running managers for the offering, and Robert W. Baird & Co. Incorporated and Cantor Fitzgerald & Co. are acting as co-managers for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on November 10, 2011. This offering is being made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained from Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2720; and from Canaccord Genuity Inc., 99 High Street, 12th Floor, Boston, MA 02110, or by calling (800) 225-6201.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About NewLink Genetics Corporation
NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. For more information please visit us at www.linkp.com.
CONTACT: NewLink Genetics Corporation Gordon Link, CFO, 515-598-2925